anti-C5aR1 monoclonal antibody TJ210
Term · Oncology and biomedicine · MLC-T-ONC-010190
A differentiated human monoclonal antibody targeting the complement component fragment 5a receptor (C5aR1, CD88), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-C5aR1 monoclonal antibody TJ210 specifically targets and binds to the N-terminus of C5aR1 expressed on subsets of tumor-promoting cells, such as myeloid-derived suppressor cells (MDSCs), neutrophils and M2 macrophages. This prevents the binding of its ligand complement factor 5a (C5a) to C5aR1 and prevents the C5aR1-mediated activation, migration and accumulation of the C5aR1-expressing cells in the tumor microenvironment (TME). This abrogates the secretion of inflammatory and angiogenic factors by these cells and restores the activation of T and natural killer (NK) cells. This results in the induction of anti-tumor immune responses and inhibits tumor cell proliferation. C5a, a factor in the complement cascade, is often overexpressed in the TME, where it attracts and activates C5aR1-expressing tumor-promoting immune cells, and contributes to tumor immune suppression.
| Identifier | MLC-T-ONC-010190 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-C5aR monoclonal antibody TJ210 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010190",
"term": "anti-C5aR1 monoclonal antibody TJ210",
"field": "Oncology and biomedicine",
"definition": "A differentiated human monoclonal antibody targeting the complement component fragment 5a receptor (C5aR1, CD88), with potential immunomodulating and antineoplastic activities. Upon administration, the anti-C5aR1 monoclonal antibody TJ210 specifically targets and binds to the N-terminus of C5aR1 expressed on subsets of tumor-promoting cells, such as myeloid-derived suppressor cells (MDSCs), neutrophils and M2 macrophages. This prevents the binding of its ligand complement factor 5a (C5a) to C5aR1 and prevents the C5aR1-mediated activation, migration and accumulation of the C5aR1-expressing cells in the tumor microenvironment (TME). This abrogates the secretion of inflammatory and angiogenic factors by these cells and restores the activation of T and natural killer (NK) cells. This results in the induction of anti-tumor immune responses and inhibits tumor cell proliferation. C5a, a factor in the complement cascade, is often overexpressed in the TME, where it attracts and activates C5aR1-expressing tumor-promoting immune cells, and contributes to tumor immune suppression.",
"synonyms": [
"anti-C5aR monoclonal antibody TJ210"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-c5ar1-monoclonal-antibody-tj210/"
}
Record 1,270 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.